Summary
On December 19, 2025, FDA approved Myqorzo ( aficamten ), marking a significant milestone in cardiovascular medicine and a foundational achievement for the drugs sponsor Cytokinetics, Incorporated (1). The drug is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardi…
Source: PharmTech.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
